Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 240

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial

Open access
Goodwin, Pamela J., Chen, Bingshu E., Gelmon, Karen A., Whelan, Timothy J., Ennis, Marguerite, Lemieux, Julie, Ligibel, Jennifer A., Hershman, Dawn L., Mayer, Ingrid A., Hobday, Timothy J., Bliss, Judith M., Rastogi, Priya, Rabaglio-Poretti, Manuela, Mukherjee, Som D., Mackey, John R., Abramson, Vandana G., Oja, Conrad, Wesolowski, Robert, Thompson, Alastair M., Rea, Daniel W., Stos, Paul M., Shepherd, Lois E., Stambolic, Vuk, Parulekar, Wendy R.·2022·JAMA

Abstract

Importance: Metformin, a biguanide commonly used to treat type 2 diabetes, has been associated with potential beneficial effects across breast cancer subtypes in observational and preclinical studies. Objective: To determine whether the administration of adjuvant metformin (vs placebo) to patients with breast cancer without diabetes improves outcomes. Design, Setting, and Participants: MA.32, a phase 3 randomized, placebo-controlled, double-blind trial, conducted in Canada, Switzerland, US, and UK, enrolled 3649 patients with high-risk nonmetastatic breast cancer receiving standard therapy between August 2010 and March 2013, with follow-up to October 2020. Interventions: Patients were randomized (stratified for hormone receptor [estrogen receptor and/or progesterone receptor {ER/PgR}] status, positive vs negative; body mass index, ≤30 vs >30; human epidermal growth factor receptor 2 [ERBB2, formerly HER2 or HER2/neu], positive vs negative; and any vs no chemotherapy) to 850 mg of oral metformin twice a day (n = 1824) or oral placebo twice a day (n = 1825) for 5 years. Main Outcomes and Measures: The primary outcome was invasive disease-free survival in hormone receptor-positive breast cancer. Of the 8 secondary outcomes, overall survival, distant relapse-free survival, and breast cancer-free interval were analyzed. Results: Of the 3649 randomized patients (mean age, 52.4 years; 3643 women [99.8%]), all (100%) were included in analyses. After a second interim analysis, futility was declared for patients who were ER/PgR-, so the primary analysis was conducted for 2533 patients who were ER/PgR+. The median duration of follow-up in the ER/PgR+ group was 96.2 months (range, 0.2-121 months). Invasive disease-free survival events occurred in 465 patients who were ER/PgR+. The incidence rates for invasive disease-free survival events were 2.78 per 100 patient-years in the metformin group vs 2.74 per 100 patient-years in the placebo group (hazard ratio [HR], 1.01; 95% CI, 0.84-1.21; P = .93), and the incidence rates for death were 1.46 per 100 patient-years in the metformin group vs 1.32 per 100 patient-years in the placebo group (HR, 1.10; 95% CI, 0.86-1.41; P = .47). Among patients who were ER/PgR-, followed up for a median of 94.1 months, incidence of invasive disease-free survival events was 3.58 vs 3.60 per 100 patient-years, respectively (HR, 1.01; 95% CI, 0.79-1.30; P = .92). None of the 3 secondary outcomes analyzed in the ER/PgR+ group had statistically significant differences. Grade 3 nonhematological toxic events occurred more frequently in patients taking metformin than in patients taking placebo (21.5% vs 17.5%, respectively, P = .003). The most common grade 3 or higher adverse events in the metformin vs placebo groups were hypertension (2.4% vs 1.9%), irregular menses (1.5% vs 1.4%), and diarrhea (1.9% vs 7.0%). Conclusions and Relevance: Among patients with high-risk operable breast cancer without diabetes, the addition of metformin vs placebo to standard breast cancer treatment did not significantly improve invasive disease-free survival. Trial Registration: ClinicalTrials.gov Identifier: NCT01101438.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.2022.6147

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 25

  1. Xu, 2015, Metformin use is associated with better survival of breast cancer patients with diabetes: a meta-analysis., Oncologist, 20, 1236, 10.1634/theoncologist.2015-0096 · DOI
  2. Lega, 2013, Association between metformin therapy and mortality after breast cancer: a population-based study., Diabetes Care, 36, 3018, 10.2337/dc12-2535 · DOI
  3. Hosio, 2020, Survival after breast cancer in women with type 2 diabetes using antidiabetic medication and statins: a retrospective cohort study., Acta Oncol, 59, 1110, 10.1080/0284186X.2020.1769858 · DOI
  4. Sonnenblick, 2017, Impact of diabetes, insulin, and metformin use on the outcome of patients with human epidermal growth factor receptor 2-positive primary breast cancer: analysis from the ALLTO Phase III randomized trial., J Clin Oncol, 35, 1421, 10.1200/JCO.2016.69.7722 · DOI · Paper page
  5. Rahmani, 2020, The effect of metformin on biomarkers associated with breast cancer outcomes: a systematic review, meta-analysis, and dose-response of randomized clinical trials., Clin Transl Oncol, 22, 37, 10.1007/s12094-019-02108-9 · DOI
  6. Goodwin, 2021, Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial., NPJ Breast Cancer, 7, 74, 10.1038/s41523-021-00275-z · DOI
  7. Saini, 2018, Metformin as an anti-cancer agent: actions and mechanisms targeting cancer stem cells., Acta Biochim Biophys Sin (Shanghai), 50, 133, 10.1093/abbs/gmx106 · DOI · Paper page
  8. Dowling, 2012, Metformin in cancer: translational challenges., J Mol Endocrinol, 48, R31, 10.1530/JME-12-0007 · DOI · Paper page
  9. Bonanni, 2012, Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial., J Clin Oncol, 30, 2593, 10.1200/JCO.2011.39.3769 · DOI · Paper page
  10. Niraula, 2012, Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study., Breast Cancer Res Treat, 135, 821, 10.1007/s10549-012-2223-1 · DOI · Paper page
  11. Hadad, 2015, Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial., Breast Cancer Res Treat, 150, 149, 10.1007/s10549-015-3307-5 · DOI
  12. Kalinsky, 2014, Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer., Cancer Invest, 32, 150, 10.3109/07357907.2014.889706 · DOI
  13. Cuyàs, 2019, The C allele of ATM rs112112617 associates with pathological complete remission rate in breast cancer patients treated with neoadjuvant metformin., Front Oncol, 9, 193, 10.3389/fonc.2019.00193 · DOI
  14. van Leeuwen, 2012, A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts., Diabetologia, 55, 1971, 10.1007/s00125-012-2537-x · DOI
  15. White, 1978, Allocation of patients to treatment groups in a controlled clinical study., Br J Cancer, 37, 849, 10.1038/bjc.1978.124 · DOI · Paper page
  16. Pimentel, 2021, The effect of metformin on sex hormones in Canadian Cancer Trials group MA.32., J Natl Cancer Inst, 113, 192, 10.1093/jnci/djaa082 · DOI
  17. Lohmann, 2017, Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32., Breast Cancer Res Treat, 164, 371, 10.1007/s10549-017-4265-x · DOI
  18. Goodwin, 2021, CA 15-3/MUC1 levels in CCTG MA.32: a breast cancer randomized trial of metformin vs placebo., JNCI Cancer Spectr, 5, 10.1093/jncics/pkab066 · DOI
  19. Hudis, 2007, Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system., J Clin Oncol, 25, 2127, 10.1200/JCO.2006.10.3523 · DOI · Paper page
  20. Chlebowski, 2006, Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women’s Intervention Nutrition Study., J Natl Cancer Inst, 98, 1767, 10.1093/jnci/djj494 · DOI · Paper page
  21. Pimentel, 2019, A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy., Breast, 48, 17, 10.1016/j.breast.2019.08.003 · DOI
  22. Zhao, 2017, A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer., Oncotarget, 8, 84224, 10.18632/oncotarget.v8i48 · doi:10.18632/oncotarget.v8i48
  23. Nanni, 2019, Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer: the MYME randomized, phase 2 clinical trial., Breast Cancer Res Treat, 174, 433, 10.1007/s10549-018-05070-2 · DOI
  24. Peairs, 2011, Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis., J Clin Oncol, 29, 40, 10.1200/JCO.2009.27.3011 · DOI · Paper page
  25. Suissa, 2012, Metformin and the risk of cancer: time-related biases in observational studies., Diabetes Care, 35, 2665, 10.2337/dc12-0788 · DOI · Paper page

Cited by

See all 240

Metadata

Authors
Goodwin, P. J., Chen, B. E., Gelmon, K. A., Whelan, T. J., Ennis, M., Lemieux, J., Ligibel, J. A., Hershman, D. L., Mayer, I. A., Hobday, T. J., Bliss, J. M., Rastogi, P., Rabaglio-Poretti, M., Mukherjee, S. D., Mackey, J. R., Abramson, V. G., Oja, C., Wesolowski, R., Thompson, A. M., Rea, D. W., Stos, P. M., Shepherd, L. E., Stambolic, V., & Parulekar, W. R.
Venue
JAMA
Published
2022-05-24
Volume
327
Issue
20
Pages
1963
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W4282916913
Cited by
240
References
2
FWCI
13.53
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jama.2022.6147
The paper
Goodwin, P. J., Chen, B. E., Gelmon, K. A., Whelan, T. J., Ennis, M., Lemieux, J., Ligibel, J. A., Hershman, D. L., Mayer, I. A., Hobday, T. J., Bliss, J. M., Rastogi, P., Rabaglio-Poretti, M., Mukherjee, S. D., Mackey, J. R., Abramson, V. G., Oja, C., Wesolowski, R., Thompson, A. M., . . . Parulekar, W. R. (2022). Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2022.6147

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.